News und Analysen

Zoetis (NYSE: ZTS) tanked after its November earnings release. Will history repeat itself pre-market on Feb. 12, when the animal healthcare company releases results for the fourth quarter of 2025

Earnings seasons can sometimes be rough. We're seeing it this time around with several AI stocks. Advanced Micro Devices' (NASDAQ: AMD) and Microsoft's (NASDAQ: MSFT) shares plunged after its recent

Telecom powerhouse AT&T (NYSE: T) is certainly a respectable company and a great dividend payer. But is it a growth stock? Hardly.

Except, for the foreseeable future, it's going to be putting up

AT&T (NYSE: T) cut its dividend by nearly 50% in 2022. That move followed the spinoff of WarnerMedia, undoing what, in hindsight, proved to be a disastrous acquisition. Those two decisions set AT&T

After underperforming broader equities over the past few years, will the healthcare sector finally rebound and deliver above-average returns from here on out? That's hard to say. Whatever the case

Cathie Wood, the CEO of Ark Invest, is known for investing in companies with strong innovative potential. That includes biotechs that specialize in gene editing, a group of techniques that could

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both

With healthcare's status as a recession-resistant industry, healthcare stocks can be a great place for dividend investors to find companies paying out steady, consistent dividends. However, it's not

On February 4, Triton Wealth Management, PLLC reported selling 481,779 shares of Knight-Swift Transportation Holdings (NYSE:KNX), an estimated $22.58 million trade based on quarterly average

Royal Caribbean (NYSE: RCL) is set to launch a river cruise business through its upscale Celebrity brand, and demand has been so strong that the cruise line doubled its expected fleet size from 10

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Cathie Wood has been getting busy on the trading floor. The recent market volatility means opportunity, and the co-founder, CEO and chief investment officer of Ark Invest doesn't shy away from

Axsome Therapeutics (NASDAQ: AXSM) has been a red-hot stock to own over the past 12 months. During that stretch, it has soared by around 75%, dwarfing the performance of the S&P 500, which is up by

Eli Lilly's (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes drug Mounjaro, which is also marketed for treating obesity outside of the U.S., Canada

Nvidia (NASDAQ: NVDA) has been one the biggest success stories in the stock market. After having spent the first 20 years of its existence as a publicly traded company producing solid but not

Eli Lilly's (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the success of the company's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss)

Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been crashing for multiple years. The last time it posted a positive gain was in 2021, when it rose by more than 60%. Back then, business was

Novo Nordisk (NYSE:NVO), a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent

Obesity is a global health crisis and is a direct or indirect cause of various health conditions. The emergence of GLP-1 agonists over the past several years has ignited one of the most significant

Healthcare stocks are not known for healthy dividends. Great for growth, yes, but often so-so for dividend yields. The average medical large-cap stock's dividend yield was 1.67% at the end of 2025

The story of Nvidia's (NASDAQ: NVDA) ascent to become the most valuable stock in the world has dominated headlines for the past several years. But what many investors may not realize is that the

Over the past five years, Axsome Therapeutics (NASDAQ: AXSM) has been on fire. The company has crushed the market in this period on the back of solid clinical and regulatory progress. At this point

Pfizer (NYSE: PFE) stock gave up 3.3% through 10:50 a.m. ET Tuesday despite delivering an earnings beat this morning.

Analysts forecast the pharmaceuticals giant would earn $0.57 per share on $16.8

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

Hindsight is perfect. It's easy now to look back and think that artificial intelligence chip pioneer Nvidia (NASDAQ: NVDA) was always destined for greatness, given that it now has the largest market